RSN00610 | PSMA-11 linker

MedKoo Cat#: 556069 | Name: RSN00610

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RSN00610, also known as PSMA-11 precursor or PSMA-11 linker, is a linker in PSMA-11 molecule. It can be sued to synthesize conjugate with imaging agent and has potential use as a tracer for PSMA-expressing tumors. This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).

Chemical Structure

RSN00610

CAS#Unknown

Theoretical Analysis

MedKoo Cat#: 556069

Name: RSN00610

CAS#: Unknown

Chemical Formula: C28H43N5O10

Exact Mass: 609.3010

Molecular Weight: 609.68

Elemental Analysis: C, 55.16; H, 7.11; N, 11.49; O, 26.24

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

PSMA-11 precursor; RSN00610; RSN-00610; RSN 00610;

IUPAC/Chemical Name

(3S,7S)-22-(3-(aminomethyl)-4-hydroxyphenyl)-5,13,20-trioxo-4,6,12,19-tetraazadocosane-1,3,7-tricarboxylic acid

InChi Key

RLGOUDVONJUXLP-SFTDATJTSA-N

InChi Code

InChI=1S/C28H43N5O10/c29-17-19-16-18(8-11-22(19)34)9-12-24(36)31-14-4-1-2-7-23(35)30-15-5-3-6-20(26(39)40)32-28(43)33-21(27(41)42)10-13-25(37)38/h8,11,16,20-21,34H,1-7,9-10,12-15,17,29H2,(H,30,35)(H,31,36)(H,37,38)(H,39,40)(H,41,42)(H2,32,33,43)/t20-,21-/m0/s1

SMILES Code

O=C(CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCCCNC(CCCCCNC(CCC1=CC=C(C(CN)=C1)O)=O)=O)=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

PSMA-11, also known as DKFZ-PSMA-11, HBED-CC-PSMA or Psma-hbed-CC, is a ligand to make gallium Ga 68-labeled PSMA-11, which has potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET). Upon intravenous administration of gallium Ga 68-labeled PSMA-11, the Glu-urea-Lys(Ahx) moiety targets and binds to PSMA-expressing tumor cells. Upon internalization, PSMA-expressing tumor cells can be detected during PET imaging. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 609.68 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Iudicello A, Boschi S, Ghedini P, Lohr F, Panareo S. Optimization of Precursor Preparation in PSMA-11 Radiolabeling to Obtain a Highly Reproducible Radiochemical Yield. Pharmaceuticals (Basel). 2022 Mar 11;15(3):343. doi: 10.3390/ph15030343. PMID: 35337140; PMCID: PMC8953397. 2: Hoffmann MA, von Eyben FE, Fischer N, Rosar F, Müller-Hübenthal J, Buchholz HG, Wieler HJ, Schreckenberger M. Comparison of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse. Cancers (Basel). 2022 Mar 14;14(6):1479. doi: 10.3390/cancers14061479. PMID: 35326629; PMCID: PMC8946234. 3: Tseng JR, Chang SH, Wu YY, Fan KH, Yu KJ, Yang LY, Hsiao IT, Liu FY, Pang ST. Impact of Three-Month Androgen Deprivation Therapy on [68Ga]Ga-PSMA-11 PET/CT Indices in Men with Advanced Prostate Cancer-Results from a Pilot Prospective Study. Cancers (Basel). 2022 Mar 4;14(5):1329. doi: 10.3390/cancers14051329. PMID: 35267637; PMCID: PMC8909781. 4: Rodnick ME, Sollert C, Stark D, Clark M, Katsifis A, Hockley BG, Parr DC, Frigell J, Henderson BD, Bruton L, Preshlock S, Abghari-Gerst M, Piert MR, Fulham MJ, Eberl S, Gagnon K, Scott PJH. Synthesis of 68Ga- radiopharmaceuticals using both generator-derived and cyclotron-produced 68Ga as exemplified by [68Ga]Ga-PSMA-11 for prostate cancer PET imaging. Nat Protoc. 2022 Mar 4. doi: 10.1038/s41596-021-00662-7. Epub ahead of print. PMID: 35246649. 5: Morawitz J, Kirchner J, Hertelendy J, Loberg C, Schimmöller L, Dabir M, Häberle L, Mamlins E, Antke C, Arsov C, Antoch G, Sawicki LM. Is there a diagnostic benefit of late-phase abdomino-pelvic PET/CT after urination as part of whole-body 68 Ga-PSMA-11 PET/CT for restaging patients with biochemical recurrence of prostate cancer after radical prostatectomy? EJNMMI Res. 2022 Mar 4;12(1):12. doi: 10.1186/s13550-022-00885-z. PMID: 35244791; PMCID: PMC8897520. 6: Rosar F, Bartholomä M, Maus S, Privé BM, Khreish F, Franssen GM, Derks YHW, Nagarajah J, Ezziddin S. 89Zr-PSMA-617 PET/CT May Reveal Local Recurrence of Prostate Cancer Unidentified by 68Ga-PSMA-11 PET/CT. Clin Nucl Med. 2022 Feb 28. doi: 10.1097/RLU.0000000000004108. Epub ahead of print. PMID: 35234197. 7: Ceci F, Rovera G, Iorio GC, Guarneri A, Chiofalo V, Passera R, Oderda M, Dall'Armellina S, Liberini V, Grimaldi S, Bellò M, Gontero P, Ricardi U, Deandreis D. Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy. Eur J Nucl Med Mol Imaging. 2022 Feb 26. doi: 10.1007/s00259-022-05741-9. Epub ahead of print. PMID: 35217883. 8: Fütterer JJ, Nagarajah J. Research Highlight: 68Ga-PSMA-11 PET Imaging for Pelvic Nodal Metastasis in Prostate Cancer. Korean J Radiol. 2022 Mar;23(3):293-294. doi: 10.3348/kjr.2021.0938. PMID: 35213092; PMCID: PMC8876656. 9: Diego RPS, Baptista GR, Filho RVAO, de Albuquerque ETB, de Castro JDV, Dos Santos KM, de Lucena Santos JÂ, da Silveira Oliveira GF, de Lucena Santos PÂ. Application of 68Ga-PSMA-11 PET/CT in the Diagnosis of Prostate Cancer Clinical Relapse. Curr Radiopharm. 2022 Feb 23. doi: 10.2174/1874471015666220223100750. Epub ahead of print. PMID: 35209836. 10: Cegla P, Wojewódzka M, Gorczewska I, Chalewska W, Łapińska G, Ochman P, Sackiewicz A, Dedecjus M. Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [68Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy. Diagnostics (Basel). 2022 Jan 29;12(2):349. doi: 10.3390/diagnostics12020349. PMID: 35204440; PMCID: PMC8871181. 11: Chandekar KR, Sood A, Kumar R, Singh H, Singh SK. 68Ga-PSMA-11 uptake in tracheal mucus plug - a potential pitfall. Nucl Med Mol Imaging. 2022 Feb;56(1):63-66. doi: 10.1007/s13139-021-00729-z. Epub 2022 Jan 31. PMID: 35186161; PMCID: PMC8828821. 12: Gauthé M, Sargos P, Benziane Ouaritini N, Barret E, Beauval JB, Brureau L, Créhange G, Dariane C, Fiard G, Fromont G, Mathieu R, Renard-Penna R, Roubaud G, Ruffion A, Rouprêt M, Ploussard G; Cancerology Committee of the French Association of Urology. Restaging of Patients with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy Using [68Ga]-PSMA-11 Positron Emission Tomography/Computed Tomography: Impact on Disease Management. Eur Urol. 2022 Apr;81(4):e87-e89. doi: 10.1016/j.eururo.2022.01.012. Epub 2022 Feb 4. PMID: 35125228. 13: Sarikaya I. Letter to the Editor: 68Ga-PSMA-11 for renal cortical PET imaging. Clin Transl Imaging. 2022 Jan 25:1-2. doi: 10.1007/s40336-021-00475-4. Epub ahead of print. PMID: 35096684; PMCID: PMC8786448. 14: Li JF, Qin LP, Wu QY, Guo XH, Yang JZ, Wan QC, Cheng MH, Xie LJ. The value of 68 Ga-PSMA-11 positron emission tomography/computerized tomography in evaluating the lacrimal and salivary glands function. Clin Rheumatol. 2022 Jan 28. doi: 10.1007/s10067-021-06038-2. Epub ahead of print. PMID: 35089469. 15: Prive BM, Peters S, Uijen MJM, Janssen MJR, van Gemert WAM, Kreissl MC, Ezziddin S, Konijnenberg MW, Nagarajah J. Letter to the Editor RE: Tumor sink effect in 68Ga-PSMA-11 PET: Myth or Reality? J Nucl Med. 2022 Jan 13:jnumed.122.263802. doi: 10.2967/jnumed.122.263802. Epub ahead of print. PMID: 35027370. 16: Zhao Q, Yang B, Dong A, Zuo C. 18F-PSMA-11 PET/MRI in Prostate Adenocarcinoma With Mucinous Features. Clin Nucl Med. 2022 Jan 11. doi: 10.1097/RLU.0000000000003995. Epub ahead of print. PMID: 35020651. 17: Xu G, Lu Y. 68Ga-PSMA-11 PET Identified Tumor Recurrence in Prostatectomy Bed With Rising PSA of 0.9 ng/mL but Negative on MRI and 18F-Fluciclovine PET Scan. Clin Nucl Med. 2022 Apr 1;47(4):378-379. doi: 10.1097/RLU.0000000000003994. PMID: 35020642. 18: Pitalua-Cortes Q, García-Perez FO, Vargas-Ahumada J, Gonzalez-Rueda S, Gomez-Argumosa E, Ignacio-Alvarez E, Soldevilla-Gallardo I, Torres-Agredo L. Head-to-Head Comparison of 68Ga-PSMA-11 and 131I in the Follow-Up of Well-Differentiated Metastatic Thyroid Cancer: A New Potential Theragnostic Agent. Front Endocrinol (Lausanne). 2021 Dec 22;12:794759. doi: 10.3389/fendo.2021.794759. PMID: 35002972; PMCID: PMC8727771. 19: Nuo Y, Li A, Yang L, Xue H, Wang F, Wang L. Efficacy of 68Ga- PSMA-11 PET/CT with biparametric MRI in diagnosing prostate cancer and predicting risk stratification: a comparative study. Quant Imaging Med Surg. 2022 Jan;12(1):53-65. doi: 10.21037/qims-21-80. PMID: 34993060; PMCID: PMC8666784. 20: Vlachostergios PJ, Niaz MJ, Thomas C, Christos PJ, Osborne JR, Margolis DJA, Khani F, Bander NH, Scherr DS, Tagawa ST. Pilot study of the diagnostic utility of 89 Zr-df-IAB2M and 68 Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer. Prostate. 2022 Mar;82(4):483-492. doi: 10.1002/pros.24294. Epub 2022 Jan 5. PMID: 34985786.